(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number
WO 2005/007035 A1

(51) International Patent Classification[7]: A61F 2/06

(21) International Application Number:
PCT/US2004/021506

(22) International Filing Date: 1 July 2004 (01.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/485,154 7 July 2003 (07.07.2003) US

(71) Applicant *(for all designated States except US)*: **MEDTRONIC VASCULAR** [US/US]; IP Legal Department, 3576 Unocal Place, Santa Rosa, CA 95403 (US).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **NOLTING, John** [US/US]; P.O. Box 14366, Santa Rosa, CA 95402 (US).

(74) Agent: **JARO, Michael**; IP Legal Department, 3576 Unocal Place, Santa Rosa, CA 95403 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COATED STENT WITH TIMED RELEASE OF MULTIPLE THERAPEUTIC AGENTS TO INHIBIT RESTENOSIS ADJACENT TO THE STENT ENDS



(57) Abstract: The present invention provides a system for treating a vascular condition that inhibits restenosis adjacent to the ends of a stent by delivering a therapeutic agent to the vessel wall at and beyond the stent ends. The system comprises a catheter and a coated stent operably coupled to the catheter. The coated stent includes a plurality of therapeutic coatings disposed on the distal and proximal ends of a stent framework. A plurality of therapeutic agents is released from the plurality of therapeutic coatings, the therapeutic agents being released sequentially to inhibit restenosis adjacent to the ends of the stent. The system may further include a therapeutic agent and a timing coating disposed on a mid-portion of the stent framework.

WO 2005/007035 A1

COATED STENT WITH TIMED RELEASE OF MULTIPLE THERAPEUTIC AGENTS TO INHIBIT RESTENOSIS ADJACENT TO THE STENT ENDS

TECHNICAL FIELD

This invention relates generally to biomedical devices that are used for treating vascular conditions. More specifically, the invention relates to a coated stent that provides timed release of multiple therapeutic agents that are positioned at the ends of the stent to inhibit restenosis at the stent ends.

BACKGROUND OF THE INVENTION

Stents are generally cylindrical-shaped devices that are radially expandable to hold open a segment of a vessel or other anatomical lumen after implantation into the lumen. Various types of stents are in use, including expandable and self-expanding stents. Expandable stents generally are conveyed to the area to be treated on balloon catheters or other expandable devices. For insertion, the stent is positioned in a compressed configuration along the delivery device, for example crimped onto a balloon that is folded or otherwise wrapped about a guide wire that is part of the delivery device. After the stent is positioned across the lesion, it is expanded by the delivery device, causing the diameter of the stent to expand. For a self-expanding stent, commonly a sheath is retracted, allowing expansion of the stent.

Stents are used in conjunction with balloon catheters in a variety of medical therapeutic applications, including intravascular angioplasty. For example, a balloon catheter device is inflated during percutaneous transluminal coronary angioplasty (PTCA) to dilate a stenotic blood vessel. The stenosis may be the result of a lesion such as a plaque or thrombus. When inflated, the pressurized balloon exerts a compressive force on the lesion, thereby increasing the inner diameter of the affected vessel. The increased interior vessel diameter facilitates improved blood flow.

Soon after the procedure, however, a significant proportion of treated vessels restenose. To prevent restenosis, a stent, constructed of a metal or polymer, is implanted within the vessel to maintain lumen size. The stent acts as a scaffold to support the lumen in an open position. Configurations of

stents include a cylindrical tube defined by a solid wall, a mesh, interconnected stents, or like segments. Exemplary stents are disclosed in U.S. Patent No. 5,292,331 to Boneau, U.S. Patent No. 6,090,127 to Globerman, U.S. Patent No. 5,133,732 to Wiktor, U.S. Patent No. 4,739,762 to Palmaz, and U.S. Patent No. 5,421,955 to Lau.

Stent insertion may cause undesirable reactions such as inflammation, infection, thrombosis, and proliferation of cell growth that occludes the passageway. Therapeutic agents that assist in preventing these conditions have been delivered to the site by coating these agents onto a stent. Restenosis is often a greater problem adjacent to the ends of a stent than it is elsewhere along the stent. This greater problem is not addressed by prior art stents that carry the same therapeutic agent at the same dose throughout the stent. The problem is also not fully addressed by prior art stents that carry only a single therapeutic agent concentrated on the ends of the stent or that carry multiple therapeutic agents that are not tailored for release at a predetermined time. Restenosis is a disease state that expresses itself differently as the disease progresses and elicits varied responses from the body's immune system at different stages of the disease. Certain therapeutic agents are most effective when released during a specific stage of the disease.

Therefore, it would be desirable to have a coated stent, a system for treating a vascular condition, and a method of inhibiting restenosis adjacent to the ends of a stent used to treat a vascular condition that overcome the aforementioned and other disadvantages.

SUMMARY OF THE INVENTION

One aspect of the present invention is a system for treating a vascular condition, comprising a catheter and a coated stent operably coupled to the catheter. The coated stent includes a plurality of therapeutic coatings disposed on the distal and proximal ends of the stent. A plurality of therapeutic agents is released from the plurality of therapeutic coatings, the therapeutic agents being released sequentially to inhibit restenosis adjacent to the ends of the stent.

Another aspect of the present invention is a coated stent. The coated stent comprises a stent framework and a plurality of therapeutic coatings disposed on the distal and proximal ends of the stent framework. A plurality of therapeutic agents is released from the plurality of therapeutic coatings, the therapeutic agents being released sequentially to inhibit restenosis adjacent to the ends of the stent.

Yet another aspect of the present invention is a method of inhibiting restenosis adjacent to the ends of a stent used to treat a vascular condition. A coated stent is provided. The coated stent includes a first and a second therapeutic coating disposed on the distal and proximal ends of a stent framework. The first therapeutic coating includes a first therapeutic agent. The second therapeutic coating includes a second therapeutic agent. The coated stent further includes a first timing coating positioned between the first and second therapeutic coatings. The first therapeutic agent is released from the first therapeutic coating. The first timing coating is actuated. The second therapeutic agent is released from the second therapeutic coating at a time controlled by the first timing coating.

The aforementioned and other features and advantages of the invention will become further apparent from the following detailed description of the presently preferred embodiments, read in conjunction with the accompanying drawings. The detailed description and drawings are merely illustrative of the invention rather than limiting, the scope of the invention being defined by the appended claims and equivalents thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an illustration of one embodiment of a system for treating a vascular condition, in accordance with the present invention;

FIG. 2 is an enlarged, fragmentary view of a coated stent in accordance with the present invention;

FIG. 3 is a graphic representation of the release of therapeutic agents from the coated stent of **FIG. 2**; and

FIG. 4 is a flow diagram of one embodiment of a method of inhibiting restenosis adjacent to the ends of a stent used to treat a vascular condition, in accordance with the present invention.

DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS

One aspect of the present invention is a system for treating a vascular condition. One embodiment of the system, in accordance with the present invention, is illustrated in **FIG. 1** at **100**. System **100** comprises a catheter **110** and a coated stent **120**. Coated stent **120** comprises a proximal end **122**, a distal end **124**, and a mid-portion **126**. Coated stent **120** includes therapeutic coatings **132**, **134**, **136**, and **138**. Therapeutic coatings **132**, **134**, and **136** are disposed on the proximal and distal ends of the stent. Therapeutic coating **138** is disposed on the mid-portion of the stent. Coated stent **120** further includes timing coatings **142**, **144**, **146**, and **148**. Timing coatings **142**, **144**, and **146** are disposed on the proximal and distal ends of the stent, alternating with therapeutic coatings **132**, **134**, and **136**. Timing coating **148** is disposed on the mid-portion of the stent.

Catheter **110** may be any catheter known in the art that is appropriate for delivering a stent to a treatment site, for example a percutaneous transluminal coronary angioplasty (PTCA) balloon catheter.

Coated stent **120** is operably coupled to catheter **110**. Coated stent **120** may comprise a variety of medical implantable materials, such as stainless steel, nitinol, tantalum, ceramic, nickel, titanium, aluminum, polymeric materials, MP35N, stainless steel, titanium ASTM F63-83 Grade 1, niobium, high carat gold K 19-22, or combinations of the above.

Coated stent **120** includes therapeutic coatings **132**, **134**, and **136**, indicated generally in **FIG. 1**, disposed on the proximal **122** and distal **124** ends of the stent. While the present embodiment includes three therapeutic coatings, one skilled in the art will recognize that a coated stent in accordance with the invention may include more coatings or may include just two coatings. The therapeutic coatings may comprise a bioerodable polymer and a therapeutic agent. The therapeutic agents released from these coatings

may be, for example, an antiproliferative agent, an antineoplastic agent, an antibiotic agent, an anti-inflammatory agent, a free radical scavenger, a protein, combinations thereof, and the like. More specifically, the therapeutic agents may be paclitaxel, dexamethasone, rapamycin, a rapamycin analog, a nonsteroidal anti-inflammatory drug, a steroidal anti-inflammatory drug, a superoxide dismutase mimic, apo A-1 Milano, combinations thereof, and the like. Each coating may release a different therapeutic agent, or the same agent may be included in more than one coating.

Stent **120** further includes timing coatings **142**, **144**, and **146**, indicated generally in **FIG. 1**, disposed on the proximal **122** and distal **124** ends of the stent. One skilled in the art will recognize that a coated stent in accordance with the present invention may include more or fewer timing coatings than the three indicated in **FIG. 1**. The timing coatings may comprise a bioerodable polymer. Timing coatings **142**, **144**, and **146** alternate with therapeutic coatings **132**, **134**, and **136**, preventing release of the therapeutic agent positioned beneath the timing coating until a predetermined time. The time of release may be controlled by characteristics of the timing coating such as the timing coating's thickness, its permeability, and its resistance to being hydrolyzed and thus eroded, and other such characteristics.

In the present embodiment, therapeutic coating **136** is positioned nearest the stent, with timing coating **146** positioned over therapeutic coating **136** to control the time at which the therapeutic agent is released from therapeutic coating **136**. Therapeutic coating **134** is positioned over timing coating **146** and is controlled by timing coating **144**. Therapeutic coating **132** is positioned over timing coating **144** and is controlled by timing coating **142**, which is the outermost of the coatings. The therapeutic and timing coatings are selected and positioned to release the therapeutic agents at the appropriate times and for the appropriate durations to most effectively inhibit restenosis adjacent to the ends of the stent.

In the present embodiment, coated stent **120** additionally includes a therapeutic coating **138** disposed on the mid-portion of the stent. A coated stent in accordance with the present invention may, however, include coatings on only the ends of the stent. Therapeutic coating **138** may release a

therapeutic agent that is different from the therapeutic agents released from therapeutic coatings **132**, **134**, and **136**, or it may display diffusion characteristics that are different from those of coatings **132**, **134**, and **136**. Timing coating **148** controls the time at which therapeutic coating **138** begins to release its therapeutic agent.

Another aspect of the present invention is a coated stent. **FIG. 2** at **200** shows an enlarged, fragmentary view of one embodiment of the coated stent, in accordance with the present invention. Coated stent **200** comprises a stent framework **210** having a proximal end **212**, a distal end **214**, and a mid-portion **216**. Coated stent **200** includes therapeutic coatings **222**, **224**, **226**, and **228**. Therapeutic coatings **222**, **224**, and **226** are disposed on the proximal and distal ends of the stent framework. Therapeutic coating **228** is disposed on a mid-portion of the stent framework. Coated stent **200** further includes timing coatings **232**, **234**, **236**, and **238**. Timing coatings **232**, **234**, and **236** are disposed on the proximal and distal ends of the stent framework, alternating with therapeutic coatings **222**, **224**, and **226**. Timing coating **238** is disposed on the mid-portion of the stent.

Stent framework **210** may comprise a variety of medical implantable materials, such as stainless steel, nitinol, tantalum, ceramic, nickel, titanium, aluminum, polymeric materials, MP35N, stainless steel, titanium ASTM F63-83 Grade 1, niobium, high carat gold K 19-22, or combinations of the above.

Therapeutic coatings **222**, **224**, and **226**, disposed on the proximal **212** and distal **214** ends of stent framework **210**, may comprise a bioerodable polymer and a therapeutic agent. The therapeutic coatings may each release a different therapeutic agent, or the same agent may be included in more than one coating. The therapeutic agents may be, for example, an antiproliferative agent, an antineoplastic agent, an antibiotic agent, an anti-inflammatory agent, a free radical scavenger, a protein, combinations thereof, and the like. More specifically, the therapeutic agents may be paclitaxel, dexamethasone, rapamycin, a rapamycin analog, a nonsteroidal anti-inflammatory drug, a steroidal anti-inflammatory drug, a superoxide dismutase mimic, apo A-1 Milano, combinations thereof, and the like. While the present embodiment includes three therapeutic coatings, one skilled in

the art will recognize that a coated stent in accordance with the invention may include more coatings or may include just two coatings.

Coated stent **200** further includes timing coatings **232**, **234**, and **236** disposed on the proximal **212** and distal **214** ends of stent framework **210**. These timing coatings may comprise a bioerodable polymer. Timing coatings **232**, **234**, and **236** alternate with therapeutic coatings **222**, **224**, and **226**, preventing release of the therapeutic agent positioned beneath the timing coating until a predetermined time. The time of release may be controlled by characteristics of the timing coating such as the timing coating's thickness, its permeability, its resistance to being hydrolyzed and thus eroded, and other such characteristics.

As shown in **FIG. 2**, therapeutic coating **226** is positioned nearest stent framework **210**, with timing coating **236** positioned over therapeutic coating **226** to control the time at which the therapeutic agent is released from therapeutic coating **226**. Therapeutic coating **224** is positioned over timing coating **236** and is controlled by timing coating **234**. Therapeutic coating **222** is positioned over timing coating **234** and is controlled by timing coating **232**, which is the outermost of the coatings.

The therapeutic and timing coatings are intended to release the therapeutic agents at the appropriate times and for the appropriate durations to most effectively inhibit restenosis adjacent to the ends of the stent. One skilled in the art will recognize that many combinations of therapeutic agents, therapeutic coatings, timing coatings, and positionings of the coatings are possible. Just one possibility is described below.

The outermost therapeutic coating, here therapeutic coating **222**, may release a therapeutic agent including, for example, a rapamycin analog. These drugs may have antibiotic properties, stop new cells from forming, and dampen inflammation. Therapeutic coating **222** may be timed by timing coating **232** to release the rapamycin analog at an appropriate time, for example within an hour of deployment of the stent in the vessel, beginning the process of inhibiting restenosis adjacent to the ends of the stent.

Timing coating **234** may then delay release of the therapeutic agent from therapeutic coating **224** for an appropriate period of time, for example

several hours after therapeutic coating **222** has finished releasing its therapeutic agent. Therapeutic coating **224** may release a superoxide dismutase mimic to break down free radicals formed as a result of basic bodily processes such as those occurring in response to injury of a vessel during deployment of a stent. Free radicals can cause additional damage to cells and tissues if not converted into less harmful products by the body's own superoxide dismutase or by a superoxide dismutase mimic. A superoxide dismutase mimic may additionally have anti-inflammatory properties.

After therapeutic coating **224** has finished releasing its therapeutic agent, timing coating **236** may delay release of the therapeutic agent from the final therapeutic coating **226** for an appropriate period of time. Therapeutic coating **226** may release a therapeutic agent such as paclitaxel, which may be most effective in inhibiting restenosis if it is released over a period of days or even months. Thus, restenosis may be inhibited for an extended period of time by this agent when released from the coating positioned nearest the stent framework.

As seen in **FIG. 2**, coated stent **200** additionally includes a therapeutic coating **228** disposed on the mid-portion of the stent framework. A coated stent in accordance with the present invention may, however, include coatings on only the ends of the stent framework. Therapeutic coating **228** may release a therapeutic agent that is different from the therapeutic agents released from therapeutic coatings **222**, **224**, and **226**. It may additionally display diffusion characteristics that are different from those of coatings **222**, **224**, and **226**. Release of the therapeutic agent from therapeutic coating **228** may be controlled by timing coating **238**.

Timing coating **238** may control release of a therapeutic agent from therapeutic coating **228**. The therapeutic agent included in therapeutic coating **228** may be delivered before, during, of after delivery of the therapeutic agents from the therapeutic coatings disposed on the edges of the stent.

FIG. 3 shows a graphic representation of the release of therapeutic agents from the coated stent of **FIG. 2**.

Yet another aspect of the present invention is a method of inhibiting restenosis adjacent to the ends of a stent used to treat a vascular condition. **FIG. 4** shows a flow diagram of one embodiment, in accordance with the present invention at **400**.

A coated stent is provided (**Block 410**). In this embodiment, the coated stent includes a first and second therapeutic coating and a first timing coating disposed on the distal and proximal ends of a stent framework. The first timing coating is positioned between the first and second therapeutic coatings. A third therapeutic coating and a second timing coating are disposed on a mid-portion of the stent framework, the second timing coating positioned over the third therapeutic coating.

The coated stent is deployed in a vessel (**Block 420**). Deployment may be accomplished by, for example, conveying the coated stent to a desired location within the vessel on a balloon catheter and inflating the balloon to deliver the stent within the vessel.

A first therapeutic agent is released from the first therapeutic coating (**Block 430**). The first therapeutic agent may be, for example, an antiproliferative agent, an antineoplastic agent, an antibiotic agent, an anti-inflammatory agent, a free radical scavenger, a protein, combinations thereof, and the like. More specifically, the therapeutic agent may be paclitaxel, dexamethasone, rapamycin, a rapamycin analog, a nonsteroidal anti-inflammatory drug, a steroidal anti-inflammatory drug, a superoxide dismutase mimic, apo A-1 Milano, combinations thereof, and the like.

The first timing coating is actuated (**Block 440**). A second therapeutic agent is released from the second therapeutic coating at a time controlled by the first timing coating (**Block 450**). In this embodiment, the first timing coating comprises a bioerodable polymer that erodes as a result of contact with the wall of the vessel. The timing coating is actuated when it begins to erode, and the second therapeutic agent is released after the timing coating has eroded. Alternatively, the time of release may be controlled by characteristics of the timing coating such as its thickness and permeability.

The second therapeutic agent is, preferably, different from the first therapeutic agent. The second therapeutic agent may be an antiproliferative

agent, an antineoplastic agent, an antibiotic agent, an anti-inflammatory agent, a free radical scavenger, a protein, combinations thereof, and the like. More specifically, the therapeutic agent may be paclitaxel, dexamethasone, rapamycin, a rapamycin analog, a nonsteroidal anti-inflammatory drug, a steroidal anti-inflammatory drug, a superoxide dismutase mimic, apo A-1 Milano, combinations thereof, and the like.

The second timing coating, positioned on the mid-portion of the stent, is actuated (**Block 450**). The third therapeutic agent is released from the mid-portion of the stent at a time controlled by the second timing coating (**Block 460**). In this embodiment, the second timing coating comprises a bioerodable polymer that erodes as a result of contact with the wall of the vessel. The timing coating is actuated when it begins to erode, and the third therapeutic agent is released after the timing coating has eroded. Alternatively, the time of release may be controlled by characteristics of the timing coating such as its thickness and permeability.

Erosion of the second timing coating may take place simultaneously with erosion of the first timing coating. The timing coatings may, however, erode at different rates and may have different durations of erosion. Therefore, the third therapeutic agent may be released from the mid-portion of the stent before, during, or after release of the first and second therapeutic agents.

While the embodiments of the invention disclosed herein are presently considered to be preferred, various changes and modifications can be made without departing from the spirit and scope of the invention. The scope of the invention is indicated in the appended claims, and all changes and modifications that come within the meaning and range of equivalents are intended to be embraced therein.

What is claimed is:

1. A system for treating a vascular condition, comprising:

a catheter; and

a coated stent operably coupled to the catheter, the coated stent including a plurality of therapeutic coatings disposed on a distal end and a proximal end of the stent, wherein a plurality of therapeutic agents is released from the plurality of therapeutic coatings, the therapeutic agents being released sequentially to inhibit restenosis adjacent to the ends of the stent.

2. The system of claim 1 wherein the therapeutic agents are selected from a group consisting of an antiproliferative agent, an antineoplastic agent, an antibiotic agent, an anti-inflammatory agent, a free radical scavenger, a protein, and combinations thereof.

3. The system of claim 1 wherein the therapeutic agents are selected from a group consisting of paclitaxel, dexamethasone, rapamycin, a rapamycin analog, a nonsteroidal anti-inflammatory drug, a steroidal anti-inflammatory drug, a superoxide dismutase mimic, apo A-1 Milano, and combinations thereof.

4. The system of claim 1 wherein each therapeutic coating comprises a bioerodable polymer and a therapeutic agent.

5. The system of claim 1 further comprising:

the coated stent including a plurality of timing coatings disposed on the distal and proximal ends of the stent, the timing coatings alternating with the therapeutic coatings.

6. The system of claim 5 wherein each timing coating comprises a bioerodable polymer.

7. The system of claim 1 wherein each timing coating prevents release of the therapeutic agent from the therapeutic coating positioned beneath the timing coating until a predetermined time.

8. The system of claim 1 further comprising:

the coated stent including at least one therapeutic coating disposed on a mid-portion of the stent.

9. The system of claim 7 further comprising:

at least one timing coating disposed on a mid-portion of the stent.

10. The system of claim 8 wherein the therapeutic coating disposed on the mid-portion of the stent releases a therapeutic agent that is different from the therapeutic agents released from the therapeutic coatings disposed on the distal and proximal ends of the stent.

11. The system of claim 8 wherein the therapeutic coating disposed on the mid-portion of the stent displays diffusion characteristics that are different from those of the therapeutic coatings disposed on the distal and proximal ends of the stent.

12. A coated stent, comprising:

a stent framework; and

a plurality of therapeutic coatings disposed on a distal end and a proximal end of the stent framework, wherein a plurality of therapeutic agents is released from the plurality of therapeutic coatings, the therapeutic agents being released sequentially to inhibit restenosis adjacent to the ends of the stent.

13. The coated stent of claim 12 wherein each therapeutic coating comprises a bioerodable polymer and a therapeutic agent.

14. The coated stent of claim 12 wherein the therapeutic agents are selected from a group consisting of an antiproliferative agent, an antineoplastic agent, an antibiotic agent, an anti-inflammatory agent, a free radical scavenger, a protein, and combinations thereof.

15. The coated stent of claim 12 wherein the therapeutic agents are selected from a group consisting of paclitaxel, dexamethasone, rapamycin, a rapamycin analog, a nonsteroidal anti-inflammatory drug, a steroidal anti-inflammatory drug, a superoxide dismutase mimic, apo A-1 Milano, and combinations thereof.

16. The coated stent of claim 12 further comprising:

a plurality of timing coatings disposed on the distal and proximal ends of the stent framework, the timing coatings alternating with the therapeutic coatings.

17. The coated stent of claim 16 wherein each timing coating comprises a bioerodable polymer.

18. The coated stent of claim 16 wherein each timing coating prevents release of the therapeutic agent from the therapeutic coating positioned beneath the timing coating until a predetermined time.

19. The coated stent of claim 12 further comprising:

at least one therapeutic coating disposed on a mid-portion of the stent framework.

20. The coated stent of claim 18 further comprising:

at least one timing coating disposed on a mid-portion of the stent framework.

21. The coated stent of claim 19 wherein the therapeutic coating disposed on the mid-portion of the stent releases a therapeutic agent that is different from the therapeutic agents released from the therapeutic coatings disposed on the distal and proximal ends of the stent.

22. The coated stent of claim 19 wherein the therapeutic coating disposed on the middle of the stent displays diffusion characteristics that are different from those of the therapeutic coatings disposed on the distal and proximal ends of the stent framework.

23. A method of inhibiting restenosis adjacent to the ends of a stent used to treat a vascular condition, comprising:

providing a coated stent, the coated stent including a first and a second therapeutic coating disposed on a distal and a proximal end of the stent, the first therapeutic coating including a first therapeutic agent, the second therapeutic coating including a second therapeutic agent, the coated stent further including a first timing coating positioned between the first and second therapeutic coatings;

deploying the coated stent in a vessel;

releasing the first therapeutic agent from the first therapeutic coating;

actuating the first timing coating; and

releasing the second therapeutic agent from the second therapeutic coating at a time controlled by the first timing coating.

24. The method of claim 23 wherein the therapeutic agents are selected from a group consisting of an antiproliferative agent, an antineoplastic agent, an antibiotic agent, an anti-inflammatory agent, a free radical scavenger, a protein, and combinations thereof.

25. The method of claim 23 wherein the therapeutic agents are selected from a group consisting of paclitaxel, dexamethasone, rapamycin, a rapamycin analog, a nonsteroidal anti-inflammatory drug, a steroidal anti-inflammatory drug, a superoxide dismutase mimic, apo A-1 Milano, and combinations thereof.

26. The method of claim 23 further comprising:

releasing a third therapeutic agent from a third therapeutic coating, the third therapeutic agent disposed on a mid-portion of the stent framework.

27. The method of claim 26 further comprising:

first actuating a second timing coating, the second timing coating disposed over the third therapeutic agent on a mid-portion of the stent framework.

28. The method of claim 23 wherein the second therapeutic agent is different from the first therapeutic agent.

29. The method of claim 26 wherein the third therapeutic agent is different from the first and second therapeutic agents.

FIG. 1



FIG. 2



FIG. 3



300

FIG. 4


400
410
Provide coated stent
420
Deploy coated stent in vessel
430
Release first therapeutic agent
440
Erode first timing coating
450
Release second therapeutic agent
460
Erode second timing coating
470
Release third therapeutic agent

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/021506

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03/099169 A (ORBUS MEDICAL TECHNOLOGIES INC) 4 December 2003 (2003-12-04) paragraph '0030! - paragraph '0043!	1-22
X	US 2003/033007 A1 (SIRHAN MOTASIM ET AL) 13 February 2003 (2003-02-13) paragraph '0043! - paragraph '0059!	1-22
X	EP 1 316 323 A (ANGIOTECH PHARM INC ; UNIV BRITISH COLUMBIA (CA)) 4 June 2003 (2003-06-04) paragraph '0028! - paragraph '0051!	1-22
A,P	EP 1 362 603 A (TERUMO CORP) 19 November 2003 (2003-11-19) paragraph '0025! - paragraph '0072!	1-22

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
12 November 2004	19/11/2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Mary, C

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

[redacted]tional application No.
PCT/US2004/021506

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.: 23-29
because they relate to subject matter not required to be searched by this Authority, namely:

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

[redacted]formation on patent family members

Int[redacted]nal Application No
PCT/US2004/021506

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03099169 A	04-12-2003	WO 03099169 A1	04-12-2003
		US 2004039441 A1	26-02-2004
US 2003033007 A1	13-02-2003	US 2002082679 A1	27-06-2002
		US 2002082685 A1	27-06-2002
		US 2002114823 A1	22-08-2002
		US 2002082678 A1	27-06-2002
		US 2002082677 A1	27-06-2002
		US 2003083646 A1	01-05-2003
		EP 1355588 A2	29-10-2003
		EP 1416884 A2	12-05-2004
		EP 1416885 A2	12-05-2004
		EP 1448116 A1	25-08-2004
		JP 2004523275 T	05-08-2004
		WO 02056790 A2	25-07-2002
		WO 03009777 A2	06-02-2003
		WO 03009778 A2	06-02-2003
		WO 03009779 A2	06-02-2003
		WO 03037223 A1	08-05-2003
		US 2003050692 A1	13-03-2003
		US 2003139801 A1	24-07-2003
		US 2003017190 A1	23-01-2003
EP 1316323 A	04-06-2003	EP 1316323 A1	04-06-2003
		AT 236674 T	15-04-2003
		AU 760901 B2	22-05-2003
		AU 1852400 A	24-07-2000
		BR 9916636 A	18-09-2001
		CA 2355873 A1	13-07-2000
		WO 0040278 A1	13-07-2000
		CN 1332645 T	23-01-2002
		DE 69906797 D1	15-05-2003
		DE 69906797 T2	12-02-2004
		DK 1140243 T3	04-08-2003
		EP 1140243 A1	10-10-2001
		ES 2191480 T3	01-09-2003
		HK 1041453 A1	15-08-2003
		JP 2002534165 T	15-10-2002
		NO 20013278 A	28-08-2001
		NZ 512307 A	31-10-2003
		PT 1140243 T	29-08-2003
		US 2002065546 A1	30-05-2002
EP 1362603 A	19-11-2003	EP 1362603 A2	19-11-2003
		JP 2004041704 A	12-02-2004
		US 2003216806 A1	20-11-2003